Vestnik Dermatologii i Venerologii

Aims & Scope

VESTNIK DERMATOLOGII I VENEROLOGII is an open-access, peer-reviewed international journal that publishes original papers in efficacy and safety of medicines, the analysis of clinical practice, and its compliance with national and international recommendations.

The primary fields of research interest of the journal are dermatology (skin and veneral diseases) and cosmetology.

VESTNIK DERMATOLOGII I VENEROLOGII cater for a wide range of readers comprising clinical and medical practitioners of general and advanced medical and clinical research, academicians, researchers, and students, as well as for the international business circle of people in the field that are establishing new skin-care products.

The journal is specially interested in research related to clinical trials, procedural dermatology, patient-centered care and immunodermatology.

Papers on research methodology, health care quality, and improving the delivery of patient care, including systematic reviews and evidence-based guidelines, are also welcomed.

VESTNIK DERMATOLOGII I VENEROLOGII founded in 1924 is the oldest journal worldwide in the field of dermatovenereology.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 1,500.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018

  Citation: 31

  Authors: A. A., E. V.

• THE ASSESSMENT OF THE INCIDENCE OF SKIN DISORDERS IN RUSSIAN FEDERATION IN 2003–2016

  Citation: 22

  Authors: A. A., A. A., L. E., E. V.

• Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

  Citation: 20

  Authors: A. A., A. L., A. V., V. R., E. V., M. M., A. V., E V., R. A.

• Dermatovenereology of Russian Federation in 2020: Working Under a Pandemic

  Citation: 20

  Authors: Alexey A., Elena V.

• Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

  Citation: 16

  Authors: A. L., A. V., A. A., V. R., M. M., A. V., S. I., E. V., R. A.

• Incidence of Syphilis in the Russian Federation Over the Period 2006–2016

  Citation: 16

  Authors: A. A., A. A., L. E.

• Epidemiology of psoriasis in the Russian Federation according to the patient registry

  Citation: 16

  Authors: Alexey A., Elena V.

• Dermatovenereologic healthcare delivery in Russian Federation. Incidence of sexually transmitted infections and skin disorders, 2013-2015

  Citation: 14

  Authors: A. A., A. A., L. E., E. V.

• A combined topical therapy of chronic dermatoses

  Citation: 13

  Authors: N. N., YE. A.

• Psoriasis: clinical and epidemiological features and therapy issues

  Citation: 13

  Authors: A. L., T. V., E. А., I., Н., T., G.